Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B

28 juli 2026 uppdaterad av: Ausper Biopharma Co., Ltd.

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Clinical Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B.

This study is a randomized, double-blind, placebo-controlled, multicenter phase 2 study to assess the efficacy and safety of AHB-137 injection in treatment-naïve participants with chronic hepatitis B.

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Beräknad)

320

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

  • Kina
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina
        • Rekrytering
        • AusperBio Investigational Site
        • Huvudutredare:
          • Yao Xie
        • Kontakt:
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Kina
        • Rekrytering
        • The Second Affiliated Hospital of Chongqing Medical University
        • Huvudutredare:
          • Peng Hu
        • Kontakt:
      • Chongqing, Chongqing Municipality, Kina
        • Rekrytering
        • AusperBio Investigational Site
        • Kontakt:
        • Huvudutredare:
          • Guicheng Wu
    • Fujian
      • Xiamen, Fujian, Kina
        • Rekrytering
        • AusperBio Investigational Site
        • Huvudutredare:
          • Qianguo Mao
        • Kontakt:
    • Guangdong
      • Guangzhou, Guangdong, Kina
        • Rekrytering
        • AusperBio Investigational Site
        • Kontakt:
        • Huvudutredare:
          • Xingfei Pan
      • Jiangmen, Guangdong, Kina
        • Rekrytering
        • AusperBio Investigational Site
        • Kontakt:
        • Huvudutredare:
          • Gang He
      • Meizhou, Guangdong, Kina
        • Rekrytering
        • AusperBio Investigational Site
        • Kontakt:
        • Huvudutredare:
          • Tianhuang Liu
      • Qingyuan, Guangdong, Kina
        • Rekrytering
        • AusperBio Investigational Site
        • Huvudutredare:
          • Xi He
        • Kontakt:
      • Shenzhen, Guangdong, Kina
        • Rekrytering
        • AusperBio Investigational Site
        • Huvudutredare:
          • Guoxin Hu
        • Kontakt:
    • Guangxi
      • Liuzhou, Guangxi, Kina
        • Rekrytering
        • AusperBio Investigational Site
        • Huvudutredare:
          • Jiaguang Hu
        • Kontakt:
    • Hubei
      • Wuhan, Hubei, Kina
        • Rekrytering
        • AusperBio Investigational Site
        • Huvudutredare:
          • Kai Dai
        • Kontakt:
      • Yichang, Hubei, Kina
        • Rekrytering
        • AusperBio Investigational Site
        • Kontakt:
        • Huvudutredare:
          • Xiaolin Zhou
    • Hunan
      • Changsha, Hunan, Kina
        • Rekrytering
        • AusperBio Investigational Site
        • Huvudutredare:
          • Jing Ma
        • Kontakt:
    • Jiangsu
      • Nanjing, Jiangsu, Kina
        • Rekrytering
        • AusperBio Investigational Site
        • Huvudutredare:
          • Jie Li
        • Kontakt:
    • Jiangxi
      • Nanchang, Jiangxi, Kina
        • Rekrytering
        • AusperBio Investigational Site
        • Huvudutredare:
          • Xiaoping Wu
        • Kontakt:
    • Jilin
      • Changchun, Jilin, Kina
        • Rekrytering
        • AusperBio Investigational Site
        • Huvudutredare:
          • Yanhang Gao
        • Kontakt:
    • Liaoning
      • Shenyang, Liaoning, Kina
        • Rekrytering
        • AusperBio Investigational Site
        • Huvudutredare:
          • Yang Ding
        • Kontakt:
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina
        • Rekrytering
        • AusperBio Investigational Site
        • Huvudutredare:
          • Liang Chen
        • Kontakt:
    • Shanxi
      • Xi’an, Shanxi, Kina
        • Rekrytering
        • AusperBio Investigational Site
        • Huvudutredare:
          • Shuangsuo Dang
        • Kontakt:
    • Sichuan
      • Chengdu, Sichuan, Kina
        • Rekrytering
        • AusperBio Investigational Site
        • Huvudutredare:
          • Li Zhu
        • Kontakt:
    • Yunan
      • Kunming, Yunan, Kina
        • Rekrytering
        • AusperBio Investigational Site
        • Huvudutredare:
          • Hui Li
        • Kontakt:
    • Zhejiang
      • Hangzhou, Zhejiang, Kina
        • Rekrytering
        • The First Affiliated Hospital of Zhejiang University school of medicine
        • Huvudutredare:
          • Yunqing Qiu
        • Kontakt:
      • Hangzhou, Zhejiang, Kina
        • Rekrytering
        • AusperBio Investigational Site
        • Huvudutredare:
          • Guoping Sheng
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • Volunteer to participate and sign the informed consent form, and are willing to complete the study in accordance with the requirements of the protocol.
  • Aged 18-65 years (including boundary values).
  • Body mass index between the range of 18-32 kg/m2 (inclusive boundary values).
  • HBsAg or HBV DNA positive for ≥ 6 months at screening and no antiviral treatment with interferon or nucleoside analogue.
  • HBsAg and HBV DNA values met protocol requirements at screening.
  • ALT < 3xULN at screening.
  • Use highly effective contraception as required.

Exclusion Criteria:

  • Uncontrolled and stable clinically significant abnormalities other than a history of chronic HBV infection.
  • Participants with other clinically significant liver diseases, previous/current manifestations of hepatic decompensation, and a history of extrahepatic diseases that may be related to HBV immune status.
  • Any serious infection other than chronic hepatitis B infection requiring intravenous anti-infective therapy within 1 month prior to randomization.
  • Hepatitis C virus (HCV) infection or < 12 months from cure at screening (HCV RNA positive within 12 months), human immunodeficiency virus (HIV) positive at screening, and syphilis positive (treponema pallidum antibody positive).
  • Significant fibrosis or cirrhosis, or liver stiffness value (LSM) > 9.0 kPa at screening.
  • Participants with confirmed or suspected liver cancer who have a history of malignancy within the past 5 years or are undergoing assessment for a possible malignancy.
  • Laboratory test results do not meet the criteria.
  • Prior/current autoimmune disease, history of vasculitis, or presence of signs, symptoms, or laboratory tests of underlying vasculitis.
  • Fridericia ' s formula corrected QT interval (QTcF) ≥ 450 msec for male participants and ≥ 470 msec for female participants at screening.
  • Allergic to AHB-137 ingredients, or history of drug allergy or other allergies.
  • Major trauma or major surgery within 3 months prior to screening, or planned surgery during the trial.
  • Participants are participating in another clinical trial or failing to wash out as required.
  • Current use or use of any immunosuppressive medication (e.g. prednisone) within 3 months prior to screening, except for short courses (≤ 2 weeks) or use of topical/inhaled steroids;Those who have used immunomodulators within 3 months prior to screening;Those who have used cytotoxic drugs within 6 months prior to screening;History of vaccination within 1 month prior to screening or a live vaccination plan during the trial.
  • Participants that require regular long-term anticoagulants.
  • Abnormal thyroid function.
  • Participants that have received any antisense oligonucleic acid, siRNA, capsid assembly modulator (CAM) antiviral drug used to treat chronic hepatitis B.
  • Any other circumstances or conditions in which, in the opinion of the investigator, the participant is inappropriate for participation in this trial.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: AHB-137
AHB-137 will be administered subcutaneously.
Läkemedel: AHB-137
AHB-137 will be administered subcutaneously.
Placebo-jämförare: Placebo
Placebo will be administered subcutaneously.
Läkemedel: Placebo
Placebo kommer att administreras subkutant.

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
HBV DNA < lower limit of quantitation (LLOQ), 10 IU/mL, HBsAg < limit of detection (LOD), 0.05 IU/mL with or without hepatitis B virus surface antibody (HBsAb) 24 weeks after discontinuation of all chronic hepatitis B treatment.
Tidsram: Up to 48 weeks.
Up to 48 weeks.
Highly sensitive HBsAg < 0.005 IU/mL and HBV DNA < LLOQ (10 IU/mL) at the end of treatment.
Tidsram: Up to 48 weeks.
Up to 48 weeks.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
HBV DNA < LLOQ, 10 IU/mL, and HBsAg < 10 IU/mL 24 weeks after discontinuation of all chronic hepatitis B treatment.
Tidsram: Up to 48 weeks.
Up to 48 weeks.
HBV DNA < LLOQ 24 weeks after discontinuation of all chronic hepatitis B treatment.
Tidsram: Up to 48 weeks.
Up to 48 weeks.
HBV DNA < LLOQ and HBsAg < 100 IU/mL 24 weeks after discontinuation of all chronic hepatitis B treatment.
Tidsram: Up to 48 weeks.
Up to 48 weeks.
HBsAg seroconversion rate 24 weeks after discontinuation of all chronic hepatitis B treatment.
Tidsram: Up to 48 weeks.
HBsAg seroconversion : serum HBsAg<LOD, and at the same time or subsequently, HBsAb>10 IU/L.
Up to 48 weeks.
HBeAg seroconversion rate 24 weeks after discontinuation of all chronic hepatitis B treatment.
Tidsram: Up to 48 weeks.
HBeAg seroconversion:HBeAg negative, with simultaneous or subsequent positivity for HBeAb.
Up to 48 weeks.
Proportion of participants who discontinued all chronic hepatitis B treatment at the end of treatment.
Tidsram: Up to 48 weeks.
Up to 48 weeks.
HBV DNA < LLOQ and HBsAg < LOD rate and HBV DNA < LLOQ and HBsAg < 10 IU/mL rate by visit.
Tidsram: Up to 48 weeks.
Up to 48 weeks.
HBsAg, HBeAg seroconversion rates by visit.
Tidsram: Up to 48 weeks.

HBsAg seroconversion: serum HBsAg<LOD, and at the same time or subsequently, HBsAb>10 IU/L.

HBeAg seroconversion: HBeAg negative, with simultaneous or subsequent positivity for HBeAb.
Up to 48 weeks.
Test Values of Virological Parameters.
Tidsram: Up to 48 weeks.
HBsAb, HBsAg, HBV DNA values and changes from baseline at each visit.
Up to 48 weeks.
Time to first achievement of HBsAg and first HBeAg seroconversion.
Tidsram: Up to 48 weeks.

HBsAg seroconversion: serum HBsAg<LOD, and at the same time or subsequently, HBsAb>10 IU/L.

HBeAg seroconversion: HBeAg negative, with simultaneous or subsequent positivity for HBeAb.
Up to 48 weeks.
Changes of the hepatitis B quality of life (HBQOL) instrument in participants compared with baseline.
Tidsram: Up to 48 weeks.
Response options range from 1 to 5 with higher scores indicating more severe impact .
Up to 48 weeks.
Changes of the score of EuroQol Five-Dimension Five-Level Scale (EQ-5D-5L) in participants compared with baseline.
Tidsram: Up to 48 weeks.
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the participant's health state.
Up to 48 weeks.
Proportion of participants with protocol-defined virologic response for HBsAg and HBV DNA.
Tidsram: Up to 48 weeks.
Up to 48 weeks.
Change from baseline in alanine aminotransferase (ALT) and noninvasive assessment of liver fibrosis at each visit.
Tidsram: Up to 48 weeks.
Up to 48 weeks.
Time to normalization of ALT without rescue therapy (for participants with abnormal baseline ALT).
Tidsram: Up to 48 weeks.
Up to 48 weeks.
AHB-137 resistance analysis.
Tidsram: Up to 48 weeks.
Method: Sequencing of HBV DNA/RNA.
Up to 48 weeks.
Proportion of participants who are HBeAb positive and HBeAg negative, and the test values of HBsAb, HBsAg and HBV DNA meet certain conditions.
Tidsram: Up to 48 weeks.
Up to 48 weeks.
Safety: number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAE) and clinically significant examination results.
Tidsram: Up to 48 weeks.
Examination including laboratory examination, electrocardiogram (ECG) examination.
Up to 48 weeks.
Proportion of participants with positive anti-drug antibody (ADA) and ADA level at each visit.
Tidsram: Up to 48 weeks.
Up to 48 weeks.
Plasma drug concentration of AHB-137.
Tidsram: Up to 48 weeks.
Up to 48 weeks.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Ausper Biopharma Co., Ltd.

Utredare

  • Huvudutredare: Peng Hu, The Second Affiliated Hospital of Chongqing Medical University
  • Huvudutredare: Yunqing Qiu, Zhejiang University

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

5 juni 2026

Primärt slutförande (Beräknad)

20 juni 2027

Avslutad studie (Beräknad)

20 juni 2028

Studieregistreringsdatum

Först inskickad

28 maj 2026

Först inskickad som uppfyllde QC-kriterierna

3 juni 2026

Första postat (Faktisk)

9 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

29 juli 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

28 juli 2026

Senast verifierad

1 juli 2026

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • AB-10-8016

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera